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Abstract 
Purpose: To describe a patient with Behçet’s disease and anterior uveitis, which was not 
cured by local and systemic corticosteroid treatments, who underwent trabeculotomy one 
week after infliximab administration.  
Methods: The patient received preoperative antibiotic therapy followed by trabeculotomy 
one week after infliximab administration. We observed ocular findings before and after 
surgery.  
Results: Anterior uveitis improved after infliximab administration. The elevated intraocular 
pressure improved after surgery and there were no intraoperative complications. Neither 
ocular inflammatory attacks nor infectious complications were found in the operated eye of 
the patient during follow-up.  
Conclusion: Trabeculotomy one week after administration of infliximab appears to be safe 
and effective in treating secondary glaucoma associated with Behçet’s disease. 
 
Introduction 
Infliximab, a humanized antibody against tumor necrosis factor-alpha (TNF-α), 
reduces uveitis attacks in patients with Behçet’s disease (BD) [1, 2], although anti-TNF-
α therapy increases the risk of infections due to the systemic blockade of TNF-α [3]. 
Cataract, glaucoma, or other vitreoretinal problems often accompany BD and patients 
may require intraocular surgery for treatment. However, it is not well understood 
whether infliximab increases the risk of infections associated with surgery or when the 
best time for intraocular surgery is after infliximab administration. 
We recently examined the safety and effectiveness of infliximab administration one 
week before cataract surgery, and neither ocular inflammatory attacks nor infectious  
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complications were found [4]. Here, we report on a male patient with BD and secondary 
glaucoma who successfully underwent trabeculotomy one week after his second 
preoperative infliximab administration without suffering any postoperative 
complications. Based on these small scale series, we suggest the appropriate timing for 
intraocular surgery in patients with BD may be one week after administration of 
infliximab. 
Case Report 
A 53-year-old Japanese man was referred to our department in July 2011 due to elevated 
intraocular pressure (IOP) with repeated anterior uveitis in his left eye since April 2011. He had lost 
sight in his right eye after recurrent uveitis and secondary glaucoma despite topical and systemic 
corticosteroid treatments and trabeculectomy performed three times in October 1998, December 
2003, and November 2005. The ophthalmic examination disclosed that his left best-corrected visual 
acuity (BCVA) was decreased (20/100), while IOP was 36 mm Hg in the right and 46 mm Hg in the left 
eye. On slit-lamp examination, both corneas were edematous due to elevated IOPs, and inflammation 
was seen in the anterior chamber (cells 2+, flare +, keratic precipitates (KP) +) and in the vitreous 
(cells 2+) of the left eye. Fundus examination showed retinal vasculitis and increased cup-to-disc ratio 
in the left eye. The patient had a history of recurrent oral aphthae and erythema nodosa on his arms. 
The HLA-B51 antigen was present in the patient and he was diagnosed with BD. 
The subject had already received topical treatment for uveitis and glaucoma of his left eye; 
therefore, we continued eye drops containing latanoprost 0.005%, timolol maleate 0.5%, dorzolamide 
hydrochloride 1%, bunazosin hydrochloride 0.01%, and betamethasone sodium phosphate 0.1%. We 
started oral prednisolone (30 mg/day), which was gradually tapered as the anterior chamber 
inflammation disappeared after 3 weeks and IOP decreased to 10–15 mm Hg. Gonioscopy with a 
Goldman 3-mirror lens showed the angle of his left eye was open and there was slight peripheral 
anterior synechiae but no neovascularization. This patient was followed once at another clinic. 
Four months later, this patient came to our department again because of elevated IOP (45–50 mm 
Hg) with inflammation in the anterior chamber (cells 2+, flare 2+, KP 2+) and the vitreous (cells +) of 
his left eye (fig. 1). Oral prednisolone was increased (30 mg/day), but there was no improvement. We 
planned glaucoma surgery following infliximab administration. The computerized tomography to 
analyze his chest did not show an abnormal lesion, but his tuberculin reaction was positive; therefore, 
he started prophylactic isoniazid before infliximab administration. 
Until the glaucoma surgery, this patient received intravenous D-mannitol (500 ml) and 
acetazolamide (500 mg) twice a day. Infliximab therapy (5 mg/kg) was intravenously administered at 
weeks 4 and 6 (fig. 1; week 0 was defined as the first day of the last uveitis attack). By the second 
infliximab administration, inflammation in the anterior chamber disappeared, although the systemic 
corticosteroid was gradually tapered. The patient underwent trabeculotomy one week after the 
second preoperative infliximab administration. Neither ocular inflammatory attacks nor infectious 
complications were found in the operated eye during postoperative follow-up. Third infliximab 
therapy was intravenously administered at week 10 (fig. 1) and every 8 weeks thereafter. The 
subject’s left eye is currently in good condition without corneal edema and inflammation in the 
anterior chamber for the last four months. Typical glaucomatous visual field defects were detected by 
Goldman perimetry, but the patient’s present left BCVA was 20/70 and the IOP was around 9 mm Hg. 
A summary of changes in the left IOP and of treatments after the last uveitis attack are shown in figure 
1. As in our previous reports, this patient received the following preoperative antibiotic therapy: 0.5% 
levofloxacin eye drops (Santen Pharmaceutical Company, Osaka, Japan) and 500 mg levofloxacin oral 
tablets (Daiichi Pharmaceutical Company, Tokyo, Japan) [4, 5].  
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Discussion 
The results from this case report demonstrate that trabeculotomy one week after 
administration of infliximab is safe and effective for a patient with BD. There were no 
adverse effects, such as infection. To our knowledge, there is only one published report 
describing glaucoma surgery in a patient with BD undergoing treatment with infliximab 
therapy [6]. In this previous report, three eyes underwent successful trabeculectomy, 
but the timing of the glaucoma surgery after the final preoperative infliximab 
administration was not described. In two reports describing cataract surgery in 
patients with BD receiving infliximab treatment [7, 8], patients underwent surgery 
about halfway through an eight-week interval between doses of infliximab. The serum 
levels of infliximab significantly correlate with its effectiveness in preventing recurrent 
episodes of uveitis [9], and this midpoint between infliximab doses may be appropriate 
for determining the timing of surgery, based on the risk of infection associated with 
drug concentration. Here, we performed trabeculotomy one week after the last 
preoperative infliximab administration without suffering any postoperative 
complications, including infection. It is expected that a high serum concentration of 
infliximab is maintained in this short period after administration; thus, we believe it to 
be a safer period for surgery than four weeks after infliximab administration in terms 
of preventing surgery-associated intraocular inflammation in BD patients. 
After the last uveitis attack, the elevated IOP lasted more than 6 weeks in our patient 
and did not seem to be transient, which is associated with anterior uveitis. It is unclear 
whether this patient was a steroid responder. Although we performed trabeculotomy 
for this patient, we also planned trabeculectomy several weeks later if the initial 
trabeculotomy was not effective. Trabeculotomy was our first choice as there is a risk 
of postoperative infection in trabeculectomy, in spite of an excellent efficacy in 
reducing IOP. Trabeculectomy with mitomycin C has provided long-term safety and 
was effective in reducing IOP in cases with secondary glaucoma associated with BD [10, 
11]. Trabeculectomy has also been successful in patients with BD treated with 
infliximab therapy [6]. However, as shown here, trabeculotomy is a good surgical 
option for secondary glaucoma associated with BD. 
Fortunately, inflammation in the anterior chamber drastically improved after the 
initial infliximab administration without the use of other systemic drugs such as 
azathioprine, colchicine, and cyclosporin. This allowed us to promptly perform 
glaucoma surgery and to preserve stable IOP for several months after the surgery. This 
patient had already lost sight in his right eye the first time we met him; therefore, we 
considered the second uveitis attack as high risk for his left eye, and consequently, 
planned emergent treatment to protect it. Infliximab may be the first choice for treating 
urgent eye conditions in BD patients. However, if this patient still shows infliximab-
resistant uveitis, we may need to add other systemic drugs immediately. 
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Fig. 1. Summary of the changes in the IOP and treatments for the last uveitis attack of the left eye. The 
first day of the last uveitis attack was defined as week 0. A line graph with open circles demonstrates 
representative IOPs at each period. Anterior uveitis and elevated IOP were successfully treated after 
preoperative infliximab administration followed by trabeculotomy one week later. Inflammation in 
the anterior chamber is described. Oral administration of prednisolone, levofloxacin hydrate, and 
isoniazid are indicated by shading, and all other agents were topically administrated. Arrows 
indicate IOPs before and after intravenous administration of D-mannitol and acetazolamide. PSL = 
Oral prednisolone (mg/day); KP = keratic precipitates; i.v. = intravenous administration of D-
mannitol (500 ml) and acetazolamide (500 mg) twice a day. 
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